Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S rRNA of the 30S subunit in the bacterial 70S ribosome.

Mechanism of Ribosomal Disruption
High-resolution structural studies have elucidated that aminoglycosides bind within the decoding center of the 30S subunit, particularly around helix 44 of 16S rRNA. Critical nucleotides involved in this interaction include A1408, A1492, and A1493. Upon drug binding, these residues undergo conformational changes that stabilize an aberrant flipped-out state, even in the presence of near-cognate tRNAs. This misregulation permits incorrect codon-anticodon pairing, resulting in the incorporation of erroneous amino acids into nascent peptides and the generation of misfolded, dysfunctional proteins.

Interference with Translation and Ribosome Dynamics
Beyond inducing translational errors, certain aminoglycosides such as streptomycin interfere with the formation of a functional initiation complex, hinder subunit joining, and impede elongation by affecting EF-G-mediated translocation. Ribosome recycling is also compromised as some aminoglycosides inhibit the concerted actions of RRF and EF-G required to dissociate the 70S complex. This culminates in ribosome stalling and sequestration of translational machinery.

Cytotoxic Consequences and Resistance
The downstream effects include the misintegration of aberrant membrane proteins, leading to compromised membrane integrity, ion leakage, and collapse of the proton motive force and ATP levels. These disruptions culminate in cell death, distinguishing aminoglycosides from bacteriostatic agents. Resistance mechanisms have evolved, including enzymatic drug modification, target methylation, ribosomal mutations, and reduced drug uptake. Detailed structural insights continue to inform the development of next-generation ribosome-targeting antibiotics.